NIKKEI 225
40,580.76 +506.07 (+1.26%) HANG SENG
17,978.57 +209.43 (+1.18%) CRUDE OIL
82.97 +0.16 (+0.19%) GOLD FUTURES
2,370.20 +36.80 (+1.58%) DOW
39,267.67 -64.18 (-0.16%) Bitcoin GBP
47,424.41 -986.70 (-2.04%)
EBS Jul 2024 7.500 call
| Previous close | 0.8000 |
| Open | 0.2500 |
| Bid | 0.7500 |
| Ask | 0.8000 |
| Strike | 7.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.2500 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 675 |
GlobeNewswireUpdate: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threa
- GlobeNewswire
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threa
- GlobeNewswire
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent’s Contract Development and Manufacturing Organization (CDMO), has clin
